These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28208059)

  • 1. Designer protein disaggregases to counter neurodegenerative disease.
    Shorter J
    Curr Opin Genet Dev; 2017 Jun; 44():1-8. PubMed ID: 28208059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering therapeutic protein disaggregases.
    Shorter J
    Mol Biol Cell; 2016 May; 27(10):1556-60. PubMed ID: 27255695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversing deleterious protein aggregation with re-engineered protein disaggregases.
    Jackrel ME; Shorter J
    Cell Cycle; 2014; 13(9):1379-83. PubMed ID: 24694655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins.
    Marrero-Winkens C; Sankaran C; Schätzl HM
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32927676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins.
    Torrente MP; Shorter J
    Prion; 2013; 7(6):457-63. PubMed ID: 24401655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering enhanced protein disaggregases for neurodegenerative disease.
    Jackrel ME; Shorter J
    Prion; 2015; 9(2):90-109. PubMed ID: 25738979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chaperone-assisted protein aggregate reactivation: Different solutions for the same problem.
    Aguado A; Fernández-Higuero JA; Moro F; Muga A
    Arch Biochem Biophys; 2015 Aug; 580():121-34. PubMed ID: 26159839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of endogenous Hsp104 chaperone in yeast models of sporadic and familial Parkinson's disease.
    Gade VR; Kardani J; Roy I
    Int J Biochem Cell Biol; 2014 Oct; 55():87-92. PubMed ID: 25161148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Insights into Hsp104 Potentiation.
    Torrente MP; Chuang E; Noll MM; Jackrel ME; Go MS; Shorter J
    J Biol Chem; 2016 Mar; 291(10):5101-15. PubMed ID: 26747608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chaperone-Mediated Protein Disaggregation Triggers Proteolytic Clearance of Intra-nuclear Protein Inclusions.
    den Brave F; Cairo LV; Jagadeesan C; Ruger-Herreros C; Mogk A; Bukau B; Jentsch S
    Cell Rep; 2020 Jun; 31(9):107680. PubMed ID: 32492414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of yeast Hsp110 homolog Sse1p suppresses ydj1-151 thermosensitivity and restores Hsp90-dependent activity.
    Goeckeler JL; Stephens A; Lee P; Caplan AJ; Brodsky JL
    Mol Biol Cell; 2002 Aug; 13(8):2760-70. PubMed ID: 12181344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.
    Jackrel ME; DeSantis ME; Martinez BA; Castellano LM; Stewart RM; Caldwell KA; Caldwell GA; Shorter J
    Cell; 2014 Jan; 156(1-2):170-82. PubMed ID: 24439375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated constitutive expression of Hsp40 chaperone Sis1 reduces TDP-43 aggregation-induced oxidative stress in Ire1 pathway dependent-manner in yeast TDP-43 proteinopathy model of amyotrophic lateral sclerosis.
    Bharathi V; Bajpai A; Parappuram IT; Patel BK
    Biochem Biophys Res Commun; 2022 Mar; 595():28-34. PubMed ID: 35093637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein-Remodeling Factors As Potential Therapeutics for Neurodegenerative Disease.
    Jackrel ME; Shorter J
    Front Neurosci; 2017; 11():99. PubMed ID: 28293166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural determinants for protein unfolding and translocation by the Hsp104 protein disaggregase.
    Lee J; Sung N; Yeo L; Chang C; Lee S; Tsai FTF
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29175998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins.
    Jackrel ME; Shorter J
    Dis Model Mech; 2014 Oct; 7(10):1175-84. PubMed ID: 25062688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparate Mutations Confer Therapeutic Gain of Hsp104 Function.
    Jackrel ME; Yee K; Tariq A; Chen AI; Shorter J
    ACS Chem Biol; 2015 Dec; 10(12):2672-9. PubMed ID: 26441009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic genetic variation revealed in diverse Hsp104 homologs.
    March ZM; Sweeney K; Kim H; Yan X; Castellano LM; Jackrel ME; Lin J; Chuang E; Gomes E; Willicott CW; Michalska K; Jedrzejczak RP; Joachimiak A; Caldwell KA; Caldwell GA; Shalem O; Shorter J
    Elife; 2020 Dec; 9():. PubMed ID: 33319748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the degradation pathway of a disease-linked aspartoacylase variant.
    Gersing SK; Wang Y; Grønbæk-Thygesen M; Kampmeyer C; Clausen L; Willemoës M; Andréasson C; Stein A; Lindorff-Larsen K; Hartmann-Petersen R
    PLoS Genet; 2021 Apr; 17(4):e1009539. PubMed ID: 33914734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain.
    Tariq A; Lin J; Noll MM; Torrente MP; Mack KL; Murillo OH; Jackrel ME; Shorter J
    FEMS Yeast Res; 2018 Aug; 18(5):. PubMed ID: 29788207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.